☆ 4.6 Review

Advances, opportunities and challenges in developing therapeutic cancer vaccines

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2024)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1

Yusuke Oji et al.

Summary: Therapeutic options for rare cancers are limited, necessitating the development of novel strategies. Our clinical study showed that a biweekly WT1 Trio peptide vaccine induced stronger immune responses against WT1 compared to a weekly WT1-CTL peptide vaccine. The vaccine was confirmed to be safe, with only one patient experiencing severe adverse events. Fifteen out of 45 patients achieved stable disease after 3 months of treatment, suggesting that WT1-targeted immunotherapy may be a potential strategy for rare cancers.

CANCERS (2023)

添加到收藏夹

Review Oncology

Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials

Fatemeh Zahedipour et al.

Summary: This systematic review aims to comprehensively evaluate the therapeutic efficacy, immune response, survival rate, and side effects of VEGF/VEGF receptor-based peptide vaccines. VEGF/VEGFR2 peptide vaccines were found to be safe and effective in inducing anti-tumor immune responses, while showing moderate clinical benefit. Further clinical trials are needed to fully evaluate their clinical effects and the correlation between immune response induction and clinical outcomes.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

添加到收藏夹

Review Oncology

Advances in immunotherapy for gynecological malignancies

Mengyan Tu et al.

Summary: Currently, surgery, chemotherapy, and radiotherapy are the main treatments for gynecological malignancies, but they have limitations when dealing with complex female diseases. Immunotherapy, as an alternative, can significantly improve the prognosis of patients and has better antitumor activities. However, the development of immunotherapy is not fast enough to meet current clinical needs, and more research is needed.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

添加到收藏夹

Letter Oncology

Clinical development of mRNA therapies against solid tumors

Dawei Wu et al.

Summary: Based on a retrospective analysis of the Trialtrove database, it was found that the clinical development of mRNA therapies against solid tumors is still in its early stages. The delivery systems have evolved from dendritic cells to lipid-based platforms, and the encoding strategies have shifted from fixed tumor antigens to personalized neoantigens. Adjuvant or maintenance therapy, as well as combination treatment with checkpoint inhibitors, are the major clinical development orientations.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial

Thiago Carvalho

NATURE MEDICINE (2023)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis

Juan Zhao et al.

Summary: This article conducted the first global bibliometric analysis of the literature on therapeutic cancer vaccines from 2013 to 2022 using VOSviewer and CiteSpace, aiming to explore the current status and potential research trends. The findings showed a consistent upward trend in both publication counts and citations, with the United States being the leading contributor. Additionally, the analysis of references and keywords revealed that therapeutic cancer vaccines have long been popular topics, while neoantigen vaccines, mRNA vaccines, combination strategies, and vaccine delivery systems are emerging research hotspots. This bibliometric study provides a comprehensive and important overview of the current knowledge and potential developments in therapeutic cancer vaccines from 2013 to 2022, serving as a valuable reference for scholars interested in further exploring this promising field.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

添加到收藏夹

Article Surgery

A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Daniel Brock Hewitt et al.

Summary: In patients with borderline resectable or locally advanced unresectable pancreatic ductal adenocarcinoma, Algenpantucel-L immunotherapy did not improve overall survival and showed similar safety profile compared to standard treatment.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Oncology

Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes

Yasunori Ueda et al.

Summary: DSP-7888, an immunotherapeutic cancer vaccine derived from WT1 protein, showed acceptable safety and clinical activity in patients with MDS. Patients with a WT1-specific immune response had longer survival.

CANCER SCIENCE (2022)

添加到收藏夹

Article Oncology

A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma

Jethro L. Hu et al.

Summary: The study used an autologous dendritic cell vaccine pulsed with lysate from a GBM stem-like cell line for treating newly diagnosed and recurrent GBM, showing that the treatment was safe and well tolerated. Some patients developed a cytotoxic T-cell response, suggesting the potential role of immunotherapy in the treatment of GBM.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy

Anne M. A. Tryggestad et al.

Summary: This study aimed to reduce the risk of biochemical relapse in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy by administering personalized dendritic cell vaccines as adjuvant therapy. The results showed promising efficacy of the vaccine in reducing biochemical relapse incidence, as well as associations between baseline immune response and vaccine response during the vaccination period. Further investigation in larger cohorts is warranted to validate these findings and explore the potential of dendritic cell vaccines in post-surgical treatment of high-risk prostate cancer.

PROSTATE (2022)

添加到收藏夹

Article Oncology

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

Shouq Alzaaqi et al.

Summary: This study investigated the immune response to peptide-based cancer vaccines targeting the WT1 tumor gene in patients with advanced sarcoma. The results showed that immune recognition of the WT1 antigen existed prior to vaccine administration, and specific antibodies could be used as immune-monitoring markers.

ONCOLOGY LETTERS (2022)

添加到收藏夹

Article Oncology

ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response

Luana Guimaraes de Sousa et al.

Summary: The combination of ISA101 and nivolumab shows promising long-term clinical outcomes in patients with incurable HPV-16(+) cancer. Increased infiltration of CD8(+) T cells and macrophages is predictive of treatment response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

R. Zhong et al.

Summary: The combination of DCVAC/LuCa and carboplatin/pemetrexed showed good tolerability and potential efficacy in treatment-naive stage IV nsq NSCLC patients without oncogenic drivers.

ESMO OPEN (2022)

添加到收藏夹

Article Hematology

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant

David J. Chung et al.

Summary: It has been found that posttransplant vaccination can improve immune responses and prolong disease-free survival in multiple myeloma patients after autologous stem cell transplantation (ASCT). A phase 1 vaccine trial was conducted to investigate the safety and effectiveness of autologous Langerhans-type dendritic cell (LC) vaccination after ASCT. The results showed that the vaccination was safe and induced antigen-specific immune reactivity.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Oncology

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers

Karen S. Anderson et al.

Summary: The study found that autologous GM-CSF-secreting breast cancer vaccines induced coordinated immune responses with limited toxicity in some patients with metastatic breast cancer, but the effects were less significant in patients with stage II-III disease and there were adverse effects. Further research is needed to determine its potential role in breast cancer treatment.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy

Yasuhiro Nagata et al.

Summary: The study aimed to determine the efficacy and biomarkers of the CHP-NY-ESO-1 vaccine in ESCC patients, revealing the vaccine's safety and potential prognostic factors.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

Markus W. Loffler et al.

Summary: Immunotherapy for hepatocellular carcinoma (HCC) holds great promise in improving clinical outcomes. HepaVac-101 combines multipeptide antigens with an immunostimulator and has shown good safety profile and immunogenicity. Further clinical evaluations are needed.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

Sant P. Chawla et al.

Summary: This study investigated the efficacy and safety of combining the CMB305 regimen with atezolizumab compared to atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma. The combination therapy resulted in improved NY-ESO-1-specific T-cell and antibody responses, but did not significantly increase progression-free survival or overall survival compared to atezolizumab alone.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes

Sebastian Himbert et al.

Summary: This study presents a novel therapeutic strategy to anchor the SARS-CoV-2 spike protein in erythrocyte liposomes. The efficacy of this red blood cell-based platform was verified, opening up new possibilities for treating COVID-19 and future virus variants.

PLOS ONE (2022)

添加到收藏夹

Article Immunology

An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases

Ana Mordoh et al.

Summary: The CSF-470 vaccine, in combination with BCG and GM-CSF, has shown potential as an adjuvant treatment for cutaneous melanoma patients, and can be used in combination with immune checkpoint inhibitors. This study provides an effective treatment option for patients with stage IIB, IIC, and III cutaneous melanoma.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Espen Basmo Ellingsen et al.

Summary: Therapeutic cancer vaccine UV1 has been studied in three phase I/IIa clinical trials for malignant melanoma, non-small cell lung cancer, and prostate cancer. The vaccine induced measurable T cell responses in 78.4% of treated patients, with superior response kinetics observed in the melanoma study. Long-term immunomonitoring showed persistent telomerase peptide-specific immune responses lasting up to 7.5 years after initial vaccination.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Douglas G. McNeel et al.

Summary: The combination of programmed cell death 1 blockade and MVI-816 is safe and can enhance tumor-specific T cells, resulting in a favorable 6-month disease control rate. The occurrence of immune-related adverse events is significantly associated with prolonged time on treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study

S. P. Lau et al.

Summary: This study demonstrates the feasibility and safety of using allogeneic lysated dendritic cell vaccine in patients with resected pancreatic ductal adenocarcinoma. The vaccine induces immune reactivity to PDAC expressed antigens and has the potential to prevent disease recurrence and progression.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Espen Basmo Ellingsen et al.

Summary: This clinical trial evaluated the efficacy of a novel therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma. It was found that the vaccine-induced T cells had clinical responses, regardless of established predictive biomarkers for checkpoint inhibitor efficacy. The combination of UV1 vaccine and checkpoint inhibitors warrants further investigation.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Immunology

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial

Cathrine Lund Lorentzen et al.

Summary: The clinical trial of arginase-1 peptide vaccine in patients with treatment-refractory solid tumors demonstrated the safety and efficacy of the vaccine in inducing peptide-specific immune responses. Additionally, some patients achieved stable disease during treatment, showcasing the potential of arginase-1 vaccination as a therapeutic approach.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice

Katarina Blagovic et al.

Summary: The study demonstrates the generation of Activating Antigen Carriers (AACs) by engineering red blood cells to encapsulate relevant tumor antigens and adjuvant polyinosinic-polycytidylic acid (poly I:C). The AACs enable targeted antigen presentation and stimulation of T cell responses, resulting in effective tumor clearance and potential therapeutic benefits. The efficacy of AAC therapy is further enhanced when combined with the chemotherapeutic agent Cisplatin. These findings support AACs as a vector-free immunotherapy strategy with broad therapeutic potential.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

Frank M. Speetjens et al.

Summary: This study is the first-in-human trial to investigate the safety and immunogenicity of Amplivant conjugated to HPV16-SLP. The results show that Amplivant-conjugated SLPs can safely induce robust HPV16-specific T cell immunity, and increasing vaccine dose is associated with more adverse events and stronger systemic T cell immunity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer

Haigang Ding et al.

Summary: Cervical cancer is a common tumor in women, and traditional treatments can cure early-stage cancer. However, advanced and metastatic stages of cervical cancer are more challenging to treat. With the emergence of novel treatments, the survival rate of patients with advanced cervical cancer has significantly increased. Monotherapy with anti-HPV vaccine ISA101 does not affect tumor growth and progression in HPV-induced cervical cancer patients, therefore combining ISA101 with immune checkpoint blockers or other immunotherapeutic approaches may be more effective.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

J. Chandra et al.

Summary: The therapeutic HPV DNA vaccine AMV002 was found to be well tolerated and to enhance specific immunity to virus-derived tumour-associated antigens in subjects previously treated for HPV-associated OPSCC. The study demonstrated the safety, tolerability and immunogenicity of AMV002 in this population.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Recent developments of RNA-based vaccines in cancer immunotherapy

Elnaz Faghfuri et al.

Summary: RNA vaccines show promising potential in cancer immunotherapy by stimulating adaptive immune responses to eliminate or reduce tumor burden. Improving RNA delivery technologies and chemical modifications can enhance the translation capacity and durability of these vaccines. Early clinical development of RNA vaccines has demonstrated safety and efficacy outcomes.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

添加到收藏夹

Article Oncology

Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma

Lei Zheng et al.

Summary: The study showed that neoadjuvant immunotherapy with GVAX for resectable PDAC is safe and feasible. Patients treated with GVAX had a longer overall survival, while those who received low-dose cyclophosphamide in addition to GVAX had significantly shorter disease-free survival.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Immunology

Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model

Zenan Zhang et al.

Summary: The study demonstrated that combination immunotherapy with MUC1-MBP vaccine and α-PD1 could enhance the anti-tumor efficacy by boosting CD8(+)T cells mediated anti-tumor cellular immunity and decreasing the number of immunosuppressive cells.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Microbiology

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody

Shiwen Peng et al.

Summary: Immunotherapy for cervical cancer targeting high-risk human papillomavirus types 16 and 18 shows promising results in preclinical studies, with pBI-11 DNA vaccine inducing strong immune responses and therapeutic effects in mouse models. Combination with TA-HPV boost and PD-1 antibody blockade improves tumor control and survival. Clinical translation of this strategy may provide a new approach for HPV16/18-associated tumors.

MBIO (2021)

添加到收藏夹

Article Oncology

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)

Craig L. Slingluff et al.

Summary: Peptide vaccines combined with toll-like receptor agonist polyICLC and low-dose metronomic cyclophosphamide showed promising results in inducing strong and durable CD4(+) T cell and antibody responses in melanoma patients. The combination therapy was well tolerated and resulted in a higher durable T cell response rate compared to previous studies.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Immunology

Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design

Vanessa M. Cowton et al.

Summary: An anti-idiotype approach was used to generate an antibody that mimics a conserved neutralizing epitope on HCV E2, which showed structural similarity to a broadly neutralizing antibody. When used as an immunogen, this antibody induced protective antibodies in a mouse model against HCV challenge.

NPJ VACCINES (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Self-assembled mRNA vaccines

Jeonghwan Kim et al.

Summary: mRNA vaccines, emerging as front-runners in the COVID-19 vaccine race, utilize advancements in RNA technology, vaccinology, and nanotechnology to design self-assembled nanoparticles for vaccine delivery, showing tremendous promise and readiness for clinical use.

ADVANCED DRUG DELIVERY REVIEWS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen et al.

Summary: The IO102/IO103 vaccine targeting IDO/PD-L1, combined with nivolumab, showed favorable safety and clinical efficacy in treating metastatic melanoma, with an 80% objective response rate and 43% complete responses. This immunomodulatory approach warrants further validation in larger randomized trials to confirm its clinical potential.

NATURE MEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

mRNA vaccine for cancer immunotherapy

Lei Miao et al.

Summary: mRNA vaccines have emerged as a promising platform for cancer immunotherapy, showcasing high potency, safe administration, rapid development potentials, and cost-effective manufacturing. However, challenges such as stability, innate immunogenicity, and inefficient in vivo delivery restrict their applications. In addressing these challenges, structural modifications and formulation methods are being researched to enhance the anti-tumor immune response.

MOLECULAR CANCER (2021)

添加到收藏夹

Review Oncology

A New Generation of Vaccines in the Age of Immunotherapy

Alfredo Addeo et al.

Summary: Cancer vaccines have been extensively studied and recent advances show promising developments. Future efforts should focus on target identification, vaccination strategies, adjuvant development, and predictive biomarkers. Cautious optimism is warranted as recent clinical trials for oncolytic vaccines show early success, with the potential to revolutionize cancer therapy.

CURRENT ONCOLOGY REPORTS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

Siqing Fu et al.

Summary: WT2725 is a WT1-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1(+) tumors in patients with HLA-A*0201(+) and/or HLA-A*0206(+). The phase I study showed that WT2725 dosing emulsion was well tolerated, with promising antitumor activity in malignancies known to overexpress the WT1 protein, especially in glioblastoma patients.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001

Ursula Wiedermann et al.

Summary: The study developed a therapeutic B-cell epitope vaccine (IMU-131/HER-Vaxx) for HER2/neu-overexpressing gastroesophageal adenocarcinoma patients. The vaccine was found to be safe and well-tolerated, inducing dose-dependent HER2-specific antibody and cellular responses, which correlated with clinical responses and prolonged progression-free survival in patients who received the highest dose of the vaccine. Further evaluation in a phase II trial combining chemotherapy with IMU-131 is ongoing.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Immunology

Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma

Masafumi Ikeda et al.

Summary: The two peptide cocktail vaccines showed good tolerability and potential usefulness against HCC, with stable disease reported in 52.9% and 35.7% of patients in the two studies, respectively. No dose-limiting toxicities were observed.

IMMUNOTHERAPY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Michael Platten et al.

Summary: Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)+ tumours.

NATURE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy

Hongxia Zhang et al.

Summary: mRNA-based cancer vaccines are a popular approach for developing personalized and effective antitumor immunotherapy, delivering tumor antigen-encoding mRNA into dendritic cells for antigen presentation and stimulating innate immune response as an adjuvant effect. A minimalist nanovaccine formulation called C1 has shown significant antitumor efficacy on tumor mouse models, highlighting the potential of mRNA vaccines targeting the immunosuppressive tumor microenvironment.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

添加到收藏夹

Article Hematology

A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients

Muzaffar H Qazilbash et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses

Denise L. Cecil et al.

Summary: The study shows that the IGFBP-2 N-terminus vaccine can induce high levels of IFNγ-secreting T cells in patients, without regulatory T cell responses. Following immunization, there was a significant increase in T-cell diversity and phenotype in patients.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Medicine, Research & Experimental

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Vilde Drageset Haakensen et al.

Summary: The NIPU study is a phase II clinical trial aiming to compare the efficacy and safety of nivolumab and ipilimumab with or without telomerase vaccine in patients with inoperable malignant pleural mesothelioma after first-line platinum-based chemotherapy. The study seeks to improve treatment response by combining checkpoint inhibition with a telomerase vaccine and also to explore mechanisms for treatment response and resistance.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial

Noor Alida Maria Bakker et al.

Summary: The HPV-16 E6/E7 DNA tattoo vaccination is an effective and safe treatment strategy for patients with uVIN, with HPV-specific T-cell responses being associated with clinical benefit.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Chantal Saberian et al.

Summary: The combination of adoptive transfer of tumor-infiltrating lymphocytes (TIL) and dendritic cells (DC) did not show significant difference in the persistence of MART-1-specific TIL compared to TIL therapy alone. Although more patients showed clinical response to TIL+DC therapy, the study was not powered to resolve differences between the two groups.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Therapeutic cancer vaccines

Mansi Saxena et al.

Summary: Therapeutic cancer vaccines aim to induce tumor regression, eradicate minimal residual disease, establish lasting anti-tumor memory, and avoid non-specific or adverse reactions. However, challenges arise due to tumor-induced immunosuppression and immunoresistance, hindering the achievement of these goals.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Oncology

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

Craig L. Slingluff et al.

Summary: Treatment with IPI + NY-ESO-1 vaccines enhanced T cell and antibody responses in patients. Patients with best clinical responses had broader antibody responses and increased T cell densities.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model

Shiwen Peng et al.

Summary: Intratumoral vaccination with TA-CIN induces strong antigen-specific CD8 + T cell responses and antitumor effects. The vaccine generates a systemic immune response that can control distal tumors and induces tumor infiltration of CD8 + T cells. PD-1 blockade synergizes with intratumoral TA-CIN vaccination leading to enhanced CD8 + T cell responses and complete regression of tumors, providing rationale for future clinical testing.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Review Immunology

Adenovirus Vectors: Excellent Tools for Vaccine Development

Jun Chang

Summary: Adenovirus, originally used for gene therapy, has seen increased utility as a vaccine vector in recent years with higher safety and immunogenicity. It is being tested for preventing infectious diseases and as cancer vaccines, with ongoing research to overcome limitations for improved vaccine development using adenovirus vectors.

IMMUNE NETWORK (2021)

添加到收藏夹

Article Oncology

A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3

Youn Jin Choi et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

Qian-Ting Wang et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Article Oncology

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

G. Travis Clifton et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination

Sejin Son et al.

NANO LETTERS (2020)

添加到收藏夹

Article Oncology

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma

Brenda De Keersmaecker et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Cell Biology

Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination

Jasper J. P. van Beek et al.

CELL REPORTS (2020)

添加到收藏夹

Article Oncology

A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer

Yasmin Hasan et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

添加到收藏夹

Article Clinical Neurology

A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma

Jeremy D. Rudnick et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2020)

添加到收藏夹

Review Immunology

Dendritic Cells and Their Role in Immunotherapy

Alycia Gardner et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

Aleksei Viktorovich Novik et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Article Oncology

Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients

H. Daiko et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Article Oncology

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+and CD4+T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

Souvik Dey et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Immunology

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

Matthew J. Frank et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function

Anvay Ukidve et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma

Hao Wang et al.

ONCOTARGETS AND THERAPY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Gal Cafri et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

Matthew S. Block et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

An implantable blood clot-based immune niche for enhanced cancer vaccination

Qin Fan et al.

SCIENCE ADVANCES (2020)

添加到收藏夹

Article Oncology

Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Jin Won Youn et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P Rocconi et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

Julie Charles et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

Jessica B. Foster et al.

HUMAN GENE THERAPY (2019)

添加到收藏夹

Article Oncology

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Martin Sebastian et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

添加到收藏夹

Article Oncology

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Alexandros Papachristofilou et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Immunology

Turning the corner on therapeutic cancer vaccines

Robert E. Hollingsworth et al.

NPJ VACCINES (2019)

添加到收藏夹

Meeting Abstract Oncology

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Howard A. Burris et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Cancer DNA vaccines: current preclinical and clinical developments and future perspectives

Alessandra Lopes et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Medicine, General & Internal

A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma

Ryogo Kikuchi et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Oncology

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

Patrick Y. Wen et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane M. Harper et al.

GYNECOLOGIC ONCOLOGY (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation

Lei Miao et al.

NATURE BIOTECHNOLOGY (2019)

添加到收藏夹

Article Oncology

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial

Erminia Massarelli et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Harm Westdorp et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Alberto A. Chiappori et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

添加到收藏夹

Article Oncology

A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

Akihiro Tsuboi et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

Douglas G. McNeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Respiratory System

History and principles of vaccination

E. Canoui et al.

REVUE DES MALADIES RESPIRATOIRES (2019)

添加到收藏夹

Article Oncology

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Nicola R. Hardwick et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

Kimberly R. Kalli et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Meeting Abstract Oncology

A phase 1 study of p53MVA vaccine in combination with pembrolizumab.

Vincent M. Chung et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dreno et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

Lina Liu et al.

MOLECULAR THERAPY (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

mRNA vaccines - a new era in vaccinology

Norbert Pardi et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹

Article Immunology

Tetanus vaccines: WHO position paper, February 2017-Recommendations

VACCINE (2018)

添加到收藏夹

Article Oncology

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

Ellen Wargowski et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Meeting Abstract Oncology

Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody

Yosuke Ota et al.

CANCER RESEARCH (2018)

添加到收藏夹

Review Immunology

The Evolving Erythrocyte: Red Blood Cells as Modulators of Innate Immunity

H. Luke Anderson et al.

JOURNAL OF IMMUNOLOGY (2018)

添加到收藏夹

Article Materials Science, Biomaterials

Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine

Ya-Nan Fan et al.

BIOMATERIALS SCIENCE (2018)

添加到收藏夹

Article Oncology

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Jennifer L. McQuade et al.

BMC CANCER (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Self-Replicating RNA Viruses for RNA Therapeutics

Kenneth Lundstrom

MOLECULES (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Hematology

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Peter G. Maslak et al.

BLOOD ADVANCES (2018)

添加到收藏夹

Article Oncology

BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma

Qi Liu et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Review Cell Biology

Dendritic cell-based immunotherapy

Rachel L. Sabado et al.

CELL RESEARCH (2017)

添加到收藏夹

Article Oncology

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Ugur Sahin et al.

NATURE (2017)

添加到收藏夹

Article Oncology

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

Jean-Jacques Grob et al.

ESMO OPEN (2017)

添加到收藏夹

Article Hematology

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Sebastien Anguille et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth

Jessica de Souza Sanches et al.

CANCER SCIENCE (2016)

添加到收藏夹

Article Oncology

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

Sofie Wilgenhof et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Johan F. Vansteenkiste et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Rare cancers: a sea of opportunity

Niki Boyd et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy

Angeliki Tiptiri-Kourpeti et al.

PHARMACOLOGY & THERAPEUTICS (2016)

添加到收藏夹

Article Oncology

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Jean-Louis Pujol et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble et al.

LANCET (2015)

添加到收藏夹

Article Oncology

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

James Schuster et al.

NEURO-ONCOLOGY (2015)

添加到收藏夹

Editorial Material Oncology

Indoleamine 2,3-dioxygenase vaccination

Mads Hald Andersen et al.

ONCOIMMUNOLOGY (2015)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

History of vaccination

Stanley Plotkin

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

添加到收藏夹

Review Biotechnology & Applied Microbiology

DNA vaccine for cancer immunotherapy

Benjamin Yang et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)

添加到收藏夹

Article Oncology

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

Eliane C. M. Zeestraten et al.

INTERNATIONAL JOURNAL OF CANCER (2013)

添加到收藏夹

Article Oncology

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Wim H. J. Kruit et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Review Biotechnology & Applied Microbiology

A novel, disruptive vaccination technology Self-adjuvanted RNActive® vaccines

Karl-Josef Kallen et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)

添加到收藏夹

Article Oncology

A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma

W. K. Chia et al.

ANNALS OF ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Medicine, General & Internal

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.

Philip W. Kantoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Hematology

Therapeutic LMP1 polyepitope vaccine for EBV-assolciated Hodgkin disease and nasopharyngeal carcinoma

J Duraiswamy et al.

BLOOD (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.